Is NCT07025369 recruiting in Scottsdale, AZ?

Yes, NCT07025369 is currently recruiting participants at its Scottsdale, AZ location. This prostate adenocarcinoma clinical trial is actively enrolling qualified participants.

How do I join the prostate adenocarcinoma clinical trial in Scottsdale?

To join this clinical trial in Scottsdale, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Scottsdale clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Prostate Adenocarcinoma Clinical Trial in Scottsdale, AZ

About This Prostate Adenocarcinoma Study in Scottsdale

This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA positron emission tomography (PET)/computed tomography (CT) in patients with high risk or very high risk prostate cancer. PSMA PET/CT has become the standard of care in imaging for high-risk prostate cancer. However, a limitation of PSMA PET/CT is its ability to detect cancer that has spread to the lymph nodes. PSMA is a protein that is usually found on the surface of normal prostate cells but is found in higher amounts on prostate tumor cells. Studies have shown that expression of PSMA is regulated by androgens (male reproductive hormones). Relugolix binds to gonadotropin-releasing hormone receptors in the pituitary gland, which blocks the pituitary gland from making the hormones follicle-stimulating hormone and luteinizing hormone. This causes the testicles to stop making testosterone. Relugolix may stop the growth of tumor cells that need testosterone to grow. PSMA PET/CT is an imaging procedure that is used to help find prostate tumor cells in the body. For this procedure, a cell-targeting molecule linked to a radioactive substance (flotufolastat F 18 in this trial) is injected into the body and travels through the blood. It attaches to PSMA that is found on the surface of prostate tumor cells. PET/CT scanners detect high concentrations of the radioactive molecule and shows where the prostate tumor cells are in the body. Giving a short course of ADT with relugolix may increase PSMA expression to detect smaller areas of prostate cancer that were not previously detected.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Age ≥ 18 years

Histological confirmation of prostate adenocarcinoma

Diagnosis of high risk or very high risk prostate cancer per National Comprehensive Cancer Network (NCCN) Risk Stratification. \[Any of the following: grade group 4 or 5, prostate-specific antigen (PSA) greater than 20, radiographic cT3 on MRI\]

Testosterone greater than or equal to 300

Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

Hemoglobin ≥ 9.0 g/dL (obtained ≤ 120 days prior to registration/randomization)

Absolute neutrophil count (ANC) ≥ 1500/mm\^3 (obtained ≤ 120 days prior to registration/randomization)

Platelet count ≥ 100,000/mm\^3 (obtained ≤ 120 days prior to registration/randomization)

Male patients who are committed to undertaking the following measures for the duration of the study and after the last dose of ORGOVYX (relugolix) for the time period specified:

Use a condom during sex while being treated and for 30 days after the last dose of ORGOVYX (relugolix)

Do not make semen donations during treatment and for 30 days after the last dose of ORGOVYX (relugolix)

Those with female partners of childbearing potential may be enrolled if they are:

Documented to be surgically sterile (i.e., vasectomy);

Committed to practicing true abstinence during treatment and for 30 days after the last ORGOVYX (relugolix) dose; or

Committed to using an effective method of contraception with their partner during treatment and for 30 days following the last dose of ORGOVYX (relugolix)

Provide written informed consent

Exclusion Criteria

Any of the following prior therapies:

Chemotherapy ≤ 2 weeks prior to registration/randomization

Androgen deprivation therapy

Pelvic radiation

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

Uncontrolled intercurrent illness including, but not limited to:

Ongoing or active infection

Symptomatic congestive heart failure

Unstable angina pectoris

Cardiac arrhythmia

Or psychiatric illness/social situations that would limit compliance with study requirements

Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm

Other active malignancy ≤ 1 year prior to registration

EXCEPTIONS: Non-melanotic skin cancer

NOTE: If there is a history of prior malignancy, they must not be receiving other active treatment for their cancer

History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

Use of P-glycoprotein inhibitors

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Scottsdale?

Yes, this clinical trial (NCT07025369) has an active research site in Scottsdale, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Adenocarcinoma Treatment Options in Scottsdale, AZ

If you're searching for prostate adenocarcinoma treatment options in Scottsdale, AZ, this clinical trial (NCT07025369) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Scottsdale research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced prostate adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

Prostate Adenocarcinoma Clinical Trial in Scottsdale, AZ

Expert Care in Scottsdale

IRB Approved

No-Cost Care

Apply for This Scottsdale Location

Why Participate?

Simple Process